预约演示

Xilio and Gilead partner up for IL-12 therapeutic development

2024-03-28

交易

临床1期引进/卖出

Gilead Sciences and Xilio Therapeutics have announced a partnership to develop IL-12 therapeutics. Credit: Tada Images via Shutterstock.

Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement IL-12he development of a tumour-activated IL-12 program.

Gilead Sciences GileXilio Therapeuticsreed to give Xilio $43.5m in upfront payments, including a cash patumourof $30 millIL-12Gilead will also provide a $13.5m initial equity investment in Xilio’s common stock at a premium. Later on, the clinical-stage biotech may be able to receive up to $604m in extra payments, in additional equity investments by Gilead, a transition fee and specified development, regulatory and sales-based milestones.

According to theGilead Sciencesio will also be eligXilioto accept tiered royalties varying from high single digits to mid-teenGileadnnual global net product sales.Xilio Gilead

With the new partnership, XiXilioill be in charge of the clinical development of XTX301 in the ongoing Phase I clinical trial (NCT05684965) through dose expansion. Once Xilio has fulfilled its role, Gilead can choose to take over the clinical development and commercialisation of XTX301, subject to the terms of the contract and an additional $75m transition fee. Before the payment of this fee, Xilio is eligible to gain up to a total of $29m in additional equity investments and a development milestone payment.

“We believe IL-12 has the Xiliotial to treat a broad range of tumour types and arXTX301ted to partner with Xilio to advance XTX301, a tumour-activated IL-12, as a monothXilio and a combination therapGileadss a variety of solid tumours,” said Dr Bill Grossman, Gilead Sciences’s seXTX301ice president of oncology clinical development in the 28 March press release.Xilio

Cidara Therapeutics gets grant for conjugates for treating viral infections

Cidara Therapeuticseutics gets grant for recombinant aav foviral infectionsfectivity with heterologous peptide

XTX301 is an IL-12 activator under development for solid tumours including, head and neck squamous cell carcinoma, melanoma and non-small cell lung cancer. The therapy, which was developed using Xilio’s proprietary tumour-activation platform, acts by activating T-lymphocyte and natural killer cell proliferation, which in turn kills cancer cells. The US-based company is using the platform to develop a pipeline of tumour-activated molecules such as cytokines, bispecifics and antibodies.

4D Molecular Therapeuticso adds to a chain of deals executed by Gilead Sciences. In the last few months, Gilead has also made headlines for its deals with CymaBay Therapeutics, Merus and Arcus Biosciences.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构